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Abstract
Multiple mechanisms likely contribute to neuronal death in Parkinson’s disease (PD), including mitochondrial dysfunction
and oxidative stress. Peroxisome proliferator-activated receptor gamma co-activator-1 alpha (PGC-1a) positively regulates
the expression of genes required for mitochondrial biogenesis and the cell’s antioxidant responses. Also, expression of PGC-
1a-regulated genes is low in substantia nigra (SN) neurons in early PD. Thus upregulation of PGC-1a is a candidate
neuroprotective strategy in PD. Here, an adeno-associated virus (AAV) was used to induce unilateral overexpression of Pgc-
1a, or a control gene, in the SN of wild-type C57BL/6CR mice. Three weeks after AAV administration, mice were treated with
saline or MPTP. Overexpression of Pgc-1a in the SN induced expression of target genes, but unexpectedly it also greatly
reduced the expression of tyrosine hydroxylase (Th) and other markers of the dopaminergic phenotype with resultant
severe loss of striatal dopamine. Reduced Th expression was associated with loss of Pitx3, a transcription factor that is
critical for the development and maintenance of dopaminergic cells. Expression of the neurotrophic factor Bdnf, which also
is regulated by Pitx3, similarly was reduced. Overexpression of Pgc-1a also led to increased sensitivity to MPTP-induced
death of Th+ neurons. Pgc-1a overexpression alone, in the absence of MPTP treatment, did not lead to cell loss in the SN or
to loss of dopaminergic terminals. These data demonstrate that overexpression of Pgc-1a results in dopamine depletion
associated with lower levels of Pitx3 and enhances susceptibility to MPTP. These data may have ramifications for
neuroprotective strategies targeting overexpression of PGC-1a in PD.
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Introduction
Parkinson’s Disease (PD) is a neurodegenerative disorder
characterized in part by loss of dopaminergic (DA) neurons of
the substantia nigra (SN). Compelling evidence indicates central
roles for mitochondrial dysfunction and oxidative stress [1–3].
Mitochondrial complex I impairment increases production of
reactive oxygen species (ROS), consistent with a rise in levels of
oxidative damage observed in the SN in PD [4]. Even in the
absence of mitochondrial dysfunction, ROS are a byproduct of
normal cellular respiration that, in the absence of adequate anti-
ROS defenses, can lead to oxidative damage. Therefore, defects in
endogenous antioxidant mechanisms can lead to ROS overload
and are implicated in neurodegenerative disorders [5].
This, in part, led to an interest in peroxisome-proliferator-
activated receptor-gamma co-activator 1 alpha (PGC-1a)a sa
potential therapeutic target in PD. PGC-1a is a transcriptional
co-activator that can be induced by oxidative stress and
coordinates the expression of multiple antioxidant programs
[6,7]. Transcription is a tightly regulated process; therefore, as a
transcriptional co-activator, PGC-1a is a tightly regulated
protein. PGC-1a has a defined pattern of tissue expression and
occurs at higher levels in tissues with high metabolic requirement
such as brown fat, skeletal muscle, kidney, heart and brain [8–
10]. PGC-1a expression increases in response to various stimuli,
such as physical exercise in muscle and hypothermia in brown fat
[11–13]. As in muscle, PGC-1a activity in neurons may be
involved in regulating neuronal mitochondrial density [14] as
well as the cellular response to oxidative stress, and ROS can
induce the PGC-1a-related expression of several genes coding for
antioxidant enzymes [6]. Several molecules that contribute to the
regulation of PGC-1a expression have been identified, including
Creb [6,15,16], Forkhead Box, Class O (FOXO), Myocyte-
Enhancer Factor 2 (MEF2), Peroxisome Proliferator-Activated
Receptor and (PPAR, PPAR) and Estrogen Related Receptor
(ERR) [17–19]. These activators of PGC-1a are variably
distributed across tissues, and the specificity of activator tissue
expression contributes to the specific regulation of PGC-1a [20].
Alternative splicing [21] and post-translational modifications
PLOS ONE | www.plosone.org 1 November 2012 | Volume 7 | Issue 11 | e48925[21,22] provide further complexity to the regulation of PGC-1a
activity.
PGC-1a has shown promise in animal models as a possible
neuroprotective target in Huntington’s disease [23] and amyotro-
phic lateral sclerosis [24,25]. In humans, variants in the PGC-1a
gene have been found to possibly affect the age of onset of HD
[26,27], Alzheimer’s disease [28] and PD [29]. Mice lacking a
functional copy of Pgc-1a, display neurodegenerative lesions in the
striatum, and are substantially more sensitive to low doses of
MPTP than wild-type littermates [6]. Furthermore, PGC-1a
target genes are under-expressed in SN neurons at early stages of
PD [30], implicating a role for low PGC-1a activity in PD. A
mechanistic link between PD and PGC-1a comes from studies of
Parkin, a gene in which loss of function mutations are associated
with autosomal recessive early-onset PD [31,32]. Parkin normally
promotes degradation of PARIS, a protein that represses PGC-1a
transcription, and therefore loss of Parkin function leads to
reduced PGC-1a activity [33]. For these reasons we hypothesized
that acute overexpression of Pgc-1a via a viral vector would
protect against MPTP toxicity, and tested this hypothesis using an
adeno-associated viral vector to overexpress full-length Pgc-1a in
the SN of wild-type mice. In contrast to previously published work
using transgenic overexpression of Pgc-1a [34] we found that
AAV-mediated overexpression of Pgc-1a sensitized dopaminergic
neurons to MPTP toxicity, and, in agreement with other work,
reduced levels of striatal dopamine in a manner similar to that seen
with AAV2/6 in female wild-type rats [35]. In addition, we found
that loss of dopaminergic markers were associated with a loss of
Pitx3, a key regulator of the dopaminergic phenotype and of the
neurotrophic factor Bdnf.
Methods
Production of AAV Viral Vectors
The full length murine Pgc-1a gene (,2.4 kb) was amplified by
PCR using the flag-HA Pgc-1a pCDNA construct as the DNA
template (generously provided by the Carles Lerin [36]). A SalI
restriction site, Kozak sequence, and ATG start codon were added
to the 59 end of the Pgc-1a full length coding region using the
forward primer 59-GTTCTGGTCGACGCCACCATGGACTA-
CAAGGACGACGATGAC-39. A stop codon and HindIII
restriction site were amplified at the 39 end of the coding region
using primer 59-GTTCTGAAGCTTTCATCTCT-
GAGCTTCCTTCAGTAA-39. The Pgc-1a PCR product was
digested sequentially with SalI and HindIII and ligated into the
same sites of the pACP-BHI plasmid (gift from Caroline Bass). The
pACP-BHI plasmid contains the CMV promoter, a multiple
cloning site and intron/polyA sequences derived from SV40.
These elements are flanked by AAV2 inverted terminal repeats.
The ligation was transformed into Escherichia coli DH5a using low
temperature (30uC) growth and recovery of the DH5a to
propagate the FHA-Pgc-1a vector. The final maxi-prep of the
AAV-expression construct was sequenced to ensure correct
insertion and the fidelity of the nucleotide sequence. Constructs
consisting of EGFP-pACP and mCherry-pACP were used as
controls. Packaging of the AAV2/10-FHA-Pgc-1a, AAV2/10-
mCherry and AAV2/10-EGFP was carried out according to the
standard triple transfection protocol to create helper virus-free
pseudotyped AAV2/10 virus [37]. An AAV2/10 rep/cap plasmid
provided the AAV2 replicase and AAV10 capsid genes [38–39],
while the pHelper plasmid (Stratagene, La Jolla, CA) provided the
adenoviral helper functions. Briefly, to produce virus, AAV- 293
cells grown in a 10 cm tissue culture dish were transfected with
10 mg of pHelper, 1.15 pmol each of AAV2/10 and AAV
expression plasmids (FHA-Pgc-1a-pACP, mCherry-pACP or
EGFP-pACP) via calcium phosphate precipitation. The cells were
harvested 72 hours later, the pellets resuspended in DMEM,
freeze-thawed and centrifuged several times to produced a
clarified viral lysate. The virus was quantified using real-time
PCR to measure the number of viral genome copies (vgc)
contained within the intact virions.
Intranigral AAV Injection
Adult (11–16 week) male C57BL/6 mice were obtained from
Charles River Laboratories, Wilmington, MA. Mice were
anesthetized with ketamine/xylazine and placed in a stereotaxic
frame (myNeurolab, Leica Microsystems) with a mouse adapter.
The tip of a pulled glass pipette (diameter) was inserted to
stereotaxic coordinates AP:22.9 mm; ML:24.0 mm;
DV:+1.2 mm, relative to bregma. Viral vector suspension in a
volume of 1.5 ml was microinjected into the right hemisphere using
0.069 ml bursts from a Nanoliter 2000 injector (World Precision
Instruments). This corresponded to 2610
10 viral genome copies
(vgc) of AAV2/10-FHA-Pgc-a and 1610
10 vgc AAV2/10-mCherry.
MPTP Treatment
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride
(MPTP; Sigma Aldrich) was re-suspended in 0.9% sterile saline
(Hospia) to a final concentration of 3.3 mg/ml MPTP (calculated
as free base). MPTP was administered via subcutaneous injection
at a dose of 20 mg/kg body weight three weeks post-stereotaxic
surgery. Injections were performed every two days for a period of
9 days (5 injections in total).
Behavioral Analysis
Five days after the last MPTP or saline injection, mice were
injected with 2 mg/kg body weight of amphetamine sulfate (Sigma
Aldrich) in 0.9% sterile saline. After 15 minutes the mice were
placed individually in a 28 (radius) 6 37 (height) cm circular
cylinder and behavior was recorded for 30 minutes after which
time the mouse was returned to the home cage. The video
recordings were scored by an individual blinded to treatment
status, according to the number of ipsiversive or contraversive
turns made, with one turn being defined as one full rotation of a
point on the animal’s head past a marked point on the cylinder.
Net scores were obtained by subtracting the number of contra-
versive turns from the number of ipsiversive turns.
Ethics Statement
All animal procedures, as described above, were approved by
the Beth Israel Deaconess Medical Center Animal Care and Use
Committee (Permit numbers: 035-2008 and 027-2011).
Immunofluorescent Staining Procedure
Two days after amphetamine-induced rotational behavior
testing, mice were sacrificed via anesthetic overdose (ketamine/
xylazine) and perfused with ice-cold 0.9% saline followed by 4%
paraformaldehyde (PFA; Boston Bioproducts). Fixed brains were
stored at 4uC in 4% PFA until cryopreservation for sectioning.
Brains were cryoprotected by dehydration in 15% sucrose in PBS
for 24 hours followed by 30% sucrose in PBS for 24 hours.
Following cryoprotection, each brain was sectioned through the
striatum, midbrain and SN at a thickness of 40 mm on a freezing
microtome. Sections were permeabilized in TBS containing
0.25% Triton-X-100 for 30 minutes. The tissue sections were
blocked in TBS +3% bovine serum albumin (BSA) for 1.5 hours at
room temperature then incubated overnight at 4uC with the
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(Roche) each diluted 1:1000 in TBS +1% BSA. The secondary
antibodies Alexa Fluor donkey anti-sheep 594 and Alexa Fluor
goat anti-rat 488 (Molecular Probes, Invitrogen) were diluted
1:1000 in the same diluent and incubated with the tissue for 1.5
hours at room temperature. Sections were mounted with
Vectashield mounting medium with DAPI (Vector Laboratories).
Immunohistochemical Staining Procedures
Immunohistochemical staining for tyrosine hydroxylase (Th)
was performed using a mouse monoclonal anti-Th antibody
(Sigma Aldrich 1:1000) and a Mouse-on-mouse kit (Vector
Laboratories, Burlingame, CA) according to the manufacturer’s
instructions. Immunohistochemistry for the dopamine transporter
(Dat) was performed using a rat anti-DAT (Millipore) primary and
a goat anti-rat IgG biotin-conjugated secondary antibody and a
standard immunostaining protocol. Briefly, free-floating brain
sections were permeabilized with 0.25% Triton-X-100 in TBS for
10 minutes and blocked in 3% normal goat serum (NGS, Jackson
Immunolabs) in TBS for 30 minutes. All antibody incubations
were performed using 1% NGS as a diluent. The sections were
incubated with a 1:5000 dilution of primary antibody overnight at
4uC and with secondary antibody diluted at 1:1000 for 45 minutes.
The ABC kit (Vector Laboratories) was used for signal amplifi-
cation and binding of the antibody was visualized using
diaminobenzidine with nickel intensification (Vector Laborato-
ries). The sections were mounted on Superfrost Plus slides (VWR)
and dehydrated through an ethanol series before clarifying with
xylene and cover-slipping with Permaslip (Alban Scientific). A
subset of samples were counterstained by immersion in thionin
solution (pH 4.2–4.4) for 5 minutes before subsequent dehydra-
tion, clarification and cover-slipping.
Quantitation of Immunostaining Intensity
For striatal densitometry, the stained sections were imaged using
a light microscope fitted with a camera (SPOT) and images were
captured using a 106 objective and fixed exposure settings.
Densitometry was performed to quantify the intensity of Th and
DAT immunostaining in the striatum ipsilateral to the microin-
jected SN and in the contralateral striatum. Specifically, using
Adobe Photoshop, a region of interest 2006200 pixels was
delineated in the striatum. The integrated density of this region
was calculated using the software. Next, a 2006200 pixel region of
interest was delineated over the adjacent cortex of the same section
and the integrated density of this area calculated by the software.
To normalize for differences in background staining intensity the
cortical integrated density measurement was subtracted from the
striatal integrated density measurement for each section analyzed.
Stereological Neuronal Counts
For stereology, the midbrain of each mouse was sectioned using
a freezing microtome into four series of 40 mm coronal sections
and one series was stained with an anti-Th antibody, as before, for
stereological cell counts in the SN. Stereology was performed using
the optical fractionator method by an investigator blinded to
treatment status. After mounting, each section in the series was
observed using a 2.5 6 objective lens and an outline was drawn
around each SN and overlaid with a 50650 counting frame using
Stereo Investigator software (MicroBrightField). The nuclei of
each Th+ cell within the boundaries of the optical fractionator (X
120, Y 120, height 10 mm; with 2 mm guard zones) was counted.
The total numbers of Th+ cells per SN were then calculated by the
optical fractionator software. A subset of samples were analyzed
for total SN neuronal counts. In this case, stereology was
performed in the same manner with a second marker used for
simultaneous counts of thionin+/Th- neurons with Th- neurons
being defined as those cells morphologically resembling neurons
and with a visible nucleolus but lacking Th immunoreactivity.
Measurement of DA and DA Metabolites
Mice were sacrificed by anesthetic overdose seven days after the
final MPTP or saline injection. Animals used for these biochemical
measurements had not undergone amphetamine-induced rota-
tional behavior testing. The brains were rapidly removed, placed
into a chilled brain matrix and sliced into 1 mm thick coronal
sections on ice. The sections were then placed into ice-cold saline.
The striatum was dissected from these 1 mm sections, snap-frozen
and used for HPLC analysis of DA and DA metabolites,
performed by the Neurochemistry Core, School of Medicine,
Vanderbilt University. The levels of DA and DA metabolites were
normalized to mg of protein input. Dopamine turnover was
calculated as follows: DA turnover = (HVA + DOPAC)/DA.
Western Blot Analysis
Brain tissue samples were homogenized in ice-cold lysis buffer
using the TissueLyser LT with 5 mm stainless steel beads
(Qiagen). Tissue was homogenized in 50 mM Tris-HCl
(pH 7.4), 150 mM NaCl and 1% Triton-X 100 supplemented
with protease inhibitors to a final concentration of 16 (Sigma-
Aldrich). Protein concentrations were determined by Bicinchoni-
nic Acid (BCA) Assay (Thermo Scientific) according to the
manufacturer’s instructions. Proteins were separated by SDS-
PAGE on an appropriate Tris-HCl gel according to standard
protocols. The membranes were blocked with 5% non-fat milk in
either 16 PBS-0.1%Tween or 16 TBS-0.1%Tween. Primary
antibodies were diluted in blocking solution in the following
manner: mouse anti-b-actin (C4) (sc-47778, Santa Cruz) 1:1000;
mouse anti-Th (T2928, Sigma Aldrich) 1:1000; rabbit anti-
cyrochrome c oxidase subunit 4 (CoxIV) 1:1000 (4850, Cell
Signaling Technologies); mouse anti-Pgc-1a 1:1000 (ST1202,
Calbiochem) and incubated on the membranes with rocking
overnight at 4uC. HRP conjugated anti-mouse IgG-HRP or anti-
rabbit IgG (Santa Cruz and Cell Signaling Technology) were
diluted 1:1000 in blocking buffer and incubated with the
membranes at room temperature for 1 hour. The LumiGOLD
ECL Western Blotting Detection Kit (SignaGen) was used
according to manufacturer’s instructions and the blots were
imaged by exposure on Amersham Hyperfilm ECL (GE
Healthcare). Band densities were quantified using Adobe Photo-
shop as before [40]. Briefly, the image was converted to grayscale
and inverted with respect to black and white (so that positive
values correspond to darker bands) and the freehand selection tool
was used to outline each band. Photoshop automatically computed
the integrated density (the product of area and mean gray value) of
each band. The integrated density of each band of interest was
normalized to the integrated density for the loading control of that
band.
Expression Analysis
After dissection as before, RNA was extracted from the striata
or SN using the RNeasy mini kit (Qiagen). After DNase treatment
the RNA was purified using the RNeasy MinElute Clean-up kit
(Qiagen) and used as a template for cDNA synthesis with High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems).
The final cDNA reaction was diluted seven-fold and 5 ul of the
reaction was used in duplicate 15 ul SYBR-Green (Applied
Biosystems) PCR reactions with primers specific to the target
gene. Cycle numbers were normalized to the numbers obtained
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interest was calculated in relation to the uninjected striatal or SN
hemisphere of the same animal by the DDCt method.
Statistical Analyses
All statistical analyses were performed in Prism (Graphpad
Software, La Jolla). For all comparisons of the microinjected
hemisphere versus the contralateral hemisphere data were
analyzed using a Student’s paired t-test. For comparisons between
mCherry and Pgc-1a overexpressing SNs, the fold-changes
relative to the contralateral sides were calculated and these values
compared using Student’s t-test. Statistical comparisons of three
groups or more were performed using a one-way ANOVA with
post hoc Dunn’s Multiple Comparison Test. Numbers of mice
indicated in the results section refer to numbers for each set of
experimental conditions.
Results
AAV2/10 Expresses Functional Pgc-1a in the Nigro-
striatal System
The AAV2/10-FHA-Pgc-1a vector was microinjected into the
right-hemisphere SN of wild-type C57BL/6CR mice. The
contralateral SN received no injection and served as control
tissue. 1.5 ml of AAV2/10-FHA-Pgc-1a, corresponding to approx-
imately 2610
10 vgc, or total intact virions injected, resulted in a
mean 66.6-fold increase in Pgc-1a expression in the microinjected
SN compared to the contralateral side (95% CI 15.73–117.6;
p=0.02) measured 5 weeks after injection (Figure 1A) by SYBR-
green PCR using a primer set that does not discriminate between
known Pgc-1a isoforms. This increase in Pgc-1a expression also
induced target gene expression above baseline levels measured
from the contralateral SN. Mean Prdx3 expression increased 2.3-
fold (95% CI 1.24–3.3; p=0.03). A 2.7-fold increase in expression
was observed for both Prdx5 (95% CI 1.13–4.27; p=0.04) and Cycs
(95% CI 1.12–4.22; p=0.04). There was a borderline significant
1.7-fold increase in mean Erra mRNA levels (95% CI 0.99 to 2.49;
p=0.05). AAV2/10-mCherry control injections did not signifi-
cantly alter levels of expression of Pgc-1a or any of its target genes.
In mice treated with 20 mg/kg MPTP (Figure 1B), the same titer
of AAV2/10-FHA-Pgc-1a virus resulted in a 37.2-fold mean
increase in Pgc-1a expression relative to the contralateral side (95%
CI 11.03–63.45; p=0.02). Again, Pgc-1a target genes were
induced: Erra mRNA levels increased by a mean value of 2.15
(95% CI 1.09–3.12; p=0.04), Prdx3 expression increased 1.6-fold
(95% CI 1.07 to 2.21; p=0.04), and Cycs increased 2.4-fold (95%
CI 1.08–3.71; p=0.04). A trend towards increased expression of
Prdx5 after Pgc-1a overexpression and MPTP treatment did not
reach statistical significance (95% CI 0.83 to 3.1; p=0.08).
The 120 kD Pgc-1a protein was detected in the pooled
samples from Pgc-1a-microinjected SNs (Figure 1C). We also
detected a strong 35–38 kDa band that corresponded to the size
of the published NT-Pgc-1a isoform [41] in the lysate from the
Pgc-1a microinjected SN and in the contralateral SN of the
same animals. This band was present only at a very low level in
the ipsilateral and contralateral SNs of mCherry mice. This may
indicate that some smaller Pgc-1a fragment may cross the
midline into the contralateral hemisphere, or that unilateral
Pgc-1a expression in one SN may have positive effects on Pgc-
1a expression in the contralateral SN. However, analysis of Pgc-
1a mRNA levels in the contralateral SN of Pgc-1a overex-
pressing animals compared to the contralateral SN of mCherry
overexpressing animals, using the same cDNA samples as for
Figure 1D, did not detect an increase in full-length Pgc-1a
mRNA in the contralateral SN from ‘crossed over’ AAV2/10-
FHA-Pgc-1a at time of sacrifice (data not shown).
The strong 35–38 kDa band seen on the western blot
(Figure 1C) after Pgc-1a overexpression is unlikely to correspond
to the published NT-Pgc-1a [41] isoform since the cDNA
construct used lacks the intronic splice site required to generate
this isoform. To investigate whether or not overexpressed full-
length Pgc-1a could be inducing expression of an endogenous,
shorter Pgc-1a transcript we measured Pgc-1a expression using
primers specific for a shorter Pgc-1a isoform (a kind gift from Jorge
Ruas, Figure 1D). Data were analyzed using a one-sample
Student’s t-test with a theoretical mean of 1, corresponding to
the baseline level of gene expression on the contralateral side, and
we detected a 0.5-fold downregulation of this shorter transcript in
the presence of AAV2/10-FHA-Pgc-1a compared to the contra-
lateral side (95% CI 0.25 to 0.76; p=0.004). Thus, the identity of
the 35–38 kDa band seen on the western blot after Pgc-1a
overexpression remains unknown. It is possible that this band
represents misfolded protein, or a breakdown product of Pgc-1a
that is not degraded as effectively as full-length Pgc-1a and retains
the Pgc-1a epitope detected by the antibody. In addition, while
this manuscript was in preparation several brain-specific Pgc-1a
isoforms originating from an alternate promoter were identified
[21]. Currently the expression-level of these novel isoforms in the
SN remain undetermined.
A control AAV2/10-egfp virus spread well throughout the SN
and was capable of transducing Th+ cells, as observed by viewing
native fluorescence of EGFP (Figure 1E, green) on brain sections
immunostained for Th (Figure 1E, red). Immunofluorescence
staining for the HA-tag of the AAV2/10-FHA-Pgc-1a construct
revealed expression of Pgc-1a in the SN (Figure 1F, green).
However, surprisingly, the majority of HA-Pgc-1a was not co-
localized with the expected pattern of Th immunofluorescence
(Figure 1F, red). In addition, higher magnification (Figure 1F, right
panel and figure 1G) revealed that the overexpressed Pgc-1a
protein (green) was both nuclear (blue, DAPI fluorescence) and
cytoplasmic.
Overexpression of Pgc-1a in the SN Increases
Mitochondrial Load in MPTP-treated Mice as Measured
by Western Blot for CoxIV
To determine whether Pgc-1a overexpression in the SN affected
mitochondrial load, western blot for CoxIV was performed on
whole-cell SN lysates (Figure 2). It can be seen that overexpression
of Pgc-1a did not significantly alter CoxIV levels in the SN of
saline-treated mice compared to the contralateral side, although
there was a trend towards an increase (mean increase of 1.6-fold;
95% CI 0.94 to 2.20 p=0.07). However, there was a significant
1.4-fold increase in CoxIV protein in the Pgc-1a overexpressing
SN of MPTP-treated mice, relative to the contralateral side,
regardless of whether the CoxIV band densitometry data was
normalized to b-actin (95% CI 1.26 to 1.57; p=0.001) or Tubb3
(95% CI 1.08 to 1.71; p=0.024; n=6, data not shown). There
was no significant difference (0.3560.33) between CoxIV band
densitometry data when Pgc-1a microinjected SN samples from
saline-treated or MPTP-treated animals were compared (95% CI
21.078 to 0.377; p=0.308). A similar immunoblot using striatal
tissue from Pgc-1a-microinjected animals did not detect increased
CoxIV protein in the striatum ipsilateral to Pgc-1a overexpression
(Figure 2, right-side blot).
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Ipsiversive Amphetamine-induced Rotational Behavior
Mice were unilaterally microinjected in the (right) SN with
AAV2/10-FHA-Pgc-1a or with AAV2/10-mCherry and 5 weeks
later were exposed to MPTP or saline. Five days after the last
saline or MPTP injection, the mice were assessed for rotational
behavior induced by intraperitoneal administration of 2 mg/kg
amphetamine (Figure 3A). Amphetamine tends to induce
ipsiversive rotations in a mouse with a unilateral DA deficit. For
this experiment, we predicted that unilateral overexpression of
Pgc-1a would protect against MPTP toxicity ipsilateral to the
injection, resulting in rotatations contraversive to the microinject-
ed side. As expected, animals unilaterally overexpressing mCherry in
the SN did not show a preferred direction of left-right rotation
after amphetamine administration, as measured by net ipsilateral
rotations/minute (Figure 3B), regardless of whether they were
saline treated (0.32 net right rotations/minute; 95% CI 21.47 to
2.10; p=0.70) or MPTP treated (20.02 net right rotations/
minute; 95% CI 22.15 to 2.11; p=0.98). However, unexpectedly,
mice that unilaterally overexpressed Pgc-1a in the SN exhibited a
strong rotational preference toward the right-side, i.e. ipsiversive to
Pgc-1a overexpression, regardless of whether the mice had received
saline (mean 4.9 net right turns/minute; 95% CI 2.70 to 7.05;
p=0.0004) or MPTP treatment (mean 4.25 net right turns/
minute; 95% CI 21.7 to 8.67; p=0.06), although the p-value for
the MPTP-treated mice was borderline. Also, the tendency to turn
Figure 1. AAV2/10 expresses functional Pgc-1a in the nigro-striatal system. A. SYBR-green PCR analysis of Pgc-1a and Pgc-1a-target gene
mRNA levels after saline treatment in mice microinjected unilaterally into the right SN with AAV2/10-FHA-Pgc-1a or AAV2/10-mCherry. mRNA levels
were normalized to 18S and fold-change gene expression was calculated relative to the contralateral SN using the DDCt method. Data were analyzed
using a paired t-test (n=6). B. The same analysis was performed after MPTP treatment (n=6). C. Western blot analysis of pooled SN samples. 40 mgo f
protein was run on a 4–20% SDS-PAGE gel and the blot was probed with anti-Pgc1a antibody. Lanes 1 & 2 are positive controls for the 37-kD and
120 kD (full-length; FL) Pgc-1a isoforms respectively. Lanes 3 & 4 contain pooled whole-protein lysates from 3 contralateral SNs and mCherry-
overexpressing (ipsilateral) SNs respectively. Lanes 5 and 6 lanes contain lysates from 3 contralateral SNs and Pgc-1a-overexpressing SNs respectively.
D. SYBR-green PCR analysis of a separate set of SN samples for the mRNAs giving rise to the 120 kD (FL) and 35–38 kD (N-terminal; NT) Pgc-1a
isoforms (n=6). E. The left panel shows native EGFP fluorescence after injection of AAV2/10-EGFP into the SN. The right panel is a merged image of
native EGPF (green) fluorescence and Th immunostaining (red). EGFP expressing Th+ cells appear orange/yellow. F. Immunofluorescence staining for
the HA-tag (green), Th (red) and DAPI (blue; Magnification: 640). The right panel shows the same immunofluorescently stained section at higher
magnification (Magnification: 6 200). G. Immunofluorescence staining of the same section shown in F shown here at higher magnification
(Magnification: 6400). Panels from left to right: anti-HA, anti-TH, DAPI, merged image.
doi:10.1371/journal.pone.0048925.g001
Adverse Effects of Pgc-1a in the SN
PLOS ONE | www.plosone.org 5 November 2012 | Volume 7 | Issue 11 | e48925towards the right side in saline treated mice was significantly
greater when the AAV2/10-FHA-Pgc-1a microinjected mice were
compared to AAV2/10-mCherry microinjected mice (95% CI 1.91
to 7.21; p=0.002). A similar tendency for mice microinjected with
AAV2/10-FHA-Pgc-1a and treated with MPTP to turn towards
the ipilateral side again did not quite reach statistical significance
when analyzed by comparing AAV2/10-FHA-Pgc-1a to AAV2/
10-mCherry microinjected mice (95% CI 29.0 to 0.46; p=0.07),
potentially due to statistical noise introduced by varying levels of
MPTP toxicity between animals. These data indicate that
unilateral overexpression of Pgc-1a leads to amphetamine-induced
ipsilateral rotational behavior, suggesting that overexpression of
Pgc-1a leads to DA depletion.
Overexpression of Pgc-1a Reduces Striatal Levels of DA
and DA Metabolites in Mouse Striatum
Stereotaxic injection of the AAV2/10-mCherry virus into the SN
did not significantly alter levels of DA or DA metabolites
(Figure 3C) as indicated by an absence of significant side-to-side
differences in striata of these animals regardless of whether the
animals were subsequently treated with saline (95% CI 0.85 to
1.01; p=0.07) or MPTP (95% CI 0.84 to 1.03; p=0.14).
In agreement with the ispiversive amphetamine-induced turning
behavior, mice unilaterally overexpressing Pgc-1a in the SN have
dramatically lower levels of DA and DA metabolites in the
striatum ipislateral to Pgc-1a overexpression compared to the
ipsilateral striatum of mCherry overexpressing mice. The mean DA
level after Pgc-1a overexpression was 13.5 ng/mg protein, whereas
in the mCherry animals this was 129.0 ng/mg protein, a
difference of 115.4 ng/mg (95% CI 101.3 to 129.6;
p=,0.0001). The mean level of DOPAC is reduced to 1.3 ng/
mg protein after Pgc-1a overexpression compared to a mean level
of 7.7 ng/mg protein after mCherry expression. For HVA the mean
level is reduced to 3.3 ng/mg protein after Pgc-1a overexpression
compared to 9.9 ng/mg protein after mCherry overexpression, and
for 3-MT Pgc-1a overexpression yields a mean value of 2.8 ng/mg
protein compared to 11.7 ng/mg protein for mCherry. Each of
these comparisons is significant at the p=,0.0001 level. In
addition, SN overexpression of Pgc-1a leads to significantly
increased DA turnover from a mean ratio of 0.2 in the
contralateral striatum to 0.58 in the ipsilateral striatum, an
increase of 0.36 (Figure 3D; 95% CI 0.13 to 0.57; p=0.004),
representing a mean 2.9-fold increase. This effect is further
pronounced after treatment with MPTP where DA turnover is
increased by 1.0 (95% CI 0.660 to 1.356; p=,0.0001) from a
mean ratio of 0.31 to 1.32 after Pgc-1a overexpression, represent-
ing a mean 4.3-fold increase.
Overexpression of Pgc-1a in the SN Leads to a Loss of
Striatal Th Immunoreactivity
Overexpression of Pgc-1a in the SN caused an average 69.4%
reduction in Th immunoreactivity, a mean reduction of
9.9610
7 AU (95% CI 4.2610
7 to 16610
7; p=0.004; Figure 4A),
from a mean adjusted integrated density of 14610
7 AU in the
contralateral striatum compared to 4.4610
7 AU in the striatum
ipsilateral to microinjection. Overexpression of mCherry in the SN
also significantly reduced Th immunoreactivity in the striatum
from an average adjusted integrated density of 12610
7 AU to
10610
7 AU, a mean reduction of 1.9610
7 AU (95% CI 0.29610
7
to 3.5610
7; p=0.03), a much lesser decrease than that seen
Figure 2. Western blot data for the mitochondrial marker CoxIV. 5 mg of whole-cell lysate from SN or striatal samples from saline or MPTP-
treated Pgc-1a-microinjected mice was run on a 4–20% gradient gel and probed with anti-CoxIV and anti-b-actin antibodies. Each pair of lanes
represents the contralateral (L) and ipsilateral (microinjected, R) SN respectively. Band densitometry data were analyzed using a paired Student’s t-test
(n=6 per group).
doi:10.1371/journal.pone.0048925.g002
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injection procedure, the virus itself, or the mCherry protein had a
mild impact on Th immunostaining in the striatum, but this
impact accounts for less than 20% of the magnitude of effect seen
following Pgc-1a overexpression. Evidence that Pgc-1a overexpres-
sion induces a reduction in levels of Th protein, beyond that seen
with mCherry is further demonstrated by western blot data
(Figure 4G) where there is no loss of Th protein in mCherry SN or
striatal samples.
As expected, MPTP treatment largely ablated Th expression in
the striatum (Figures 4A and 4D) and this loss of Th immuno-
reactivity was not exacerbated by overexpression of either mCherry
(95% CI 22.1610
7 to 5.0610
7; p=0.38) or Pgc-1a (95% CI
21.4610
7 to 3.4610
7; p=0.38), potentially reflecting a floor
effect.
Immunoreactivity for the DA transporter (Dat; Figure 4B) was
not significantly altered by mCherry overexpression with a mean
difference of 2.7610
769.3610
7 between striatal hemispheres
(95% CI 22.3610
8 to 1.7610
8; p=0.77) or Pgc-1a with a mean
difference of 2.2610
767.0610
7 (95% CI 21.7610
8 to 1.2610
8;
p=0.75) prior to MPTP treatment, indicating no significant loss of
dopaminergic terminals after overexpression of either gene.
Stereological cell counts of Th+ neurons in the SN (Figures 4C,
4E and 4F) revealed an increased average number of Th+ neurons
Figure 3. Amphetamine-induced rotational behavior and HPLC analysis of striatal DA. A. Mean number of ipsilateral and contralateral
turns made by each group over the 30-minute test period following an IP injection of 2 mg/kg amphetamine. The data for average number of
ipsilateral and contralateral turns made per group were compared using a 2-tailed t-test (mCherry/saline n=12, mCherry/MPTP n=9, Pgc-1a/saline
n=12, Pgc-1a/MPTP n=10). All relevant statistically significant comparisons are indicated on the graph. B. Box and whiskers plot of net ipsilateral
turns per minute per group averaged across each group. Data were analyzed by one-way ANOVA, all relevant statistically significant comparisons are
shown on the graph. C. Mean levels of striatal DA per mg of protein in the ipsilateral and contralateral (cntrl) striatum of each treatment group. Data
were analyzed by paired t-test. (mCherry/saline n=14, mCherry/MPTP n=15, Pgc-1a/saline n=15, Pgc-1a/MPTP n=16) D. DA turnover in each
treatment group. Data were analyzed by paired t-test for within group comparisons and Student’s t-test for between group comparisons.
doi:10.1371/journal.pone.0048925.g003
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densitometry with line graphs showing the integrated density of Th immunoreactivity for each animal analyzed. In the line graphs, for each animal a
line connects the results for the uninjected side (contralateral, cntrl) and the microinjected side (mCherry or PGC-1a) (mCherry/saline n=9, mCherry/
MPTP n=8, Pgc-1a/saline n=9, Pgc-1a/MPTP n=8). B. Representative images of the striatum used for Dat densitometry with line graphs showing
the integrated density of Dat immunoreactivity for each animal analyzed (mCherry/saline n=8, mCherry/MPTP n=10, Pgc-1a/saline n=11, Pgc-1a/
MPTP n=10). C. Representative images of the SN used for Th+ cell stereological analysis with line graphs showing the number of Th+ cells for each
animal analyzed (mCherry/saline n=10, mCherry/MPTP n=8, Pgc-1a/saline n=11, Pgc-1a/MPTP n=10). D. Striatal Th immunoreactivity data for all
treatment groups. Ipsilateral and contralateral striatal Th immunoreactivity within each treatment group was analyzed using a paired Student’s t-test
(mCherry/saline n=9, mCherry/MPTP n=8, Pgc-1a/saline n=9, Pgc-1a/MPTP n=8). All significant comparisons are indicated on the graph. E. SN Th+
stereological cell count data for all treatment groups. The number of Th+ cells in the ipsilateral vs contralateral SNs within each treatment group were
analyzed using a paired t-test. (mCherry/saline n=10, Pgc-1a/saline n=11). All significant comparisons are indicated on the graph. F. SN stereology
data from MPTP-treated animals (mCherry and Pgc-1a) showing the number of Th+ neurons, Th- neurons (thionin staining) and total SN neurons
(combined data). Data were analyzed using paired t-tests to compare the contralateral and ipsilateral (microinjected) SNs in each treatment group
and Student’s t-test for comparing between groups. (mCherry/MPTP n=8, Pgc-1a/MPTP n=10). G. Western blot analysis of Th immunoreactivity in
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contralateral SN in saline-treated animals (Figure 4E). From an
average 4978 Th+ cells per SN to an average 6323 Th+ cells per
SN, a mean difference of 1345 Th+ cells (95% CI 93.9 to 2595;
p=0.038). In contrast, Pgc-1a overexpression did not affect the
number of Th+ cells in the SN of saline-treated animals. The
mean number of Th+ cells was comparable between the
contralateral side (4124 Th+ cells) and the Pgc-1a overexpressing
side (4170 Th+ cells; 95% CI 21820 to 1795; p=1.0). However,
as ascertained from total cell counts, Pgc-1a overexpression caused
a significant decrease in Th+ cell survival following MPTP
treatment (Figure 4F), from a mean 3057 Th+ cells on the
contralateral side to 1975 Th+ cells on the Pgc-1a overexpressing
side, a mean difference of 1082 TH+ cells (95% CI 117 to 2047;
p=0.03). In addition, we found that Pgc-1a overexpression did
not significantly alter the number of thionin+/Th- neurons (628
contralateral, 521 ipsilateral, mean difference 108; 95% CI
2294.1 to 509.5; p=0.56). Therefore, the significant difference
in mean total cell counts between the contralateral SN (3686
neurons) and the Pgc-1a overexpressing SN (2496 neurons, mean
difference 1190; 95% CI 232.8 to 2146; p=0.02) after MPTP
treatment was attributed predominantly to increased Th+ cell
death in response to MPTP treatment. This increased loss of Th+
cells was not observed in mCherry microinjected SNs after MPTP.
Overexpression of Pgc-1a in the SN Decreases Expression
of Dopaminergic Cell Markers
Loss of Th at the protein level after Pgc-1a overexpression was
confirmed by western blot using whole-cell lysates derived from
gross dissected SN tissue samples (Figure 4G). By this measure
mean Th levels were reduced by 57.5% following Pgc-1a
overexpression in the SN ipsilateral to the injection compared to
the contralateral side in the saline treated animals, a difference of
0.9054 AU (95% CI 0.487 to 1.324; p=0.03) and by 76.8% in the
MPTP treated mice, a difference of 0.935 AU (95% CI 0.432 to
1.44; p=0.005; data not shown). In contrast, no reduction in Th
protein levels was observed by western blot using whole-cell lysates
derived from gross dissected ipsilateral SN tissue samples from
mCherry overexpressors compared to the contralateral side. A
similar pattern of results was also seen for striatal samples
(Figure 4G). Quantitative SYBR-green PCR was performed using
gene-specific primers and cDNA derived from gross dissected
microinjected-SN and contralateral SN tissue (data not shown).
Relative mean expression of Th was reduced to 0.125 (95% CI
0.124 to 0.238; p=,0.0001; n=6), Dat was reduced to 0.08 (95%
CI 0.02 to 0.142; p=,0.0001; n=5) and Vmat was reduced to
0.146 (95% CI 0.056 to 0.237; p=,0.0001; n=5) in Pgc-1a
overexpressing SN tissue compared to a defined mean of 1 for the
contralateral SN.
These markers of the dopaminergic phenotype were also
reduced in the SN when the mean fold-change in gene expression
(again, calculated for the side ipsilateral to microinjection relative
to the contralateral) for Pgc-1a overexpressing mice was compared
to that for mCherry overexpressing mice (Figure 5A). Again, the
effects were striking; Th expression was reduced after Pgc-1a
overexpression to a mean level of 0.12560.004 compared to
0.7660.113 after mCherry, a mean difference of 0.660.13 (95%
CI 0.34 to 0.93; p=0.0008). Dat expression was reduced to
0.0860.02 after Pgc-1a overexpression compared to 0.9460.22
after mCherry overexpression a difference of 0.8660.24 (95% CI
0.31 to 1.413; p=0.006). Vmat2 expression was also reduced from
0.9260.2 after mCherry overexpression to 0.14660.03 after Pgc-1a
expression a difference of 0.77560.25 (95% CI 0.21 to 1.3;
p=0.013).
Over-expression of Pgc-1a in the SN Decreases
Expression of the Neurotrophic Factor Bdnf
To ascertain possible reasons for increased sensitivity to MPTP-
induced reduction in Th+ cells in the Pgc-1a over-expressing SN of
MPTP-treated mice, SYBR-green quantitative PCR was per-
formed using the SNs of Pgc-1a-microinjected animals to
determine the mRNA level of the growth factors Gdnf and Bdnf
(Figure 5B). Although the level of Gdnf was unchanged between the
contralateral and Pgc-1a-microinjected SN, Bdnf mRNA levels
were significantly decreased in the Pgc-1a overexpressing SNs
compared to the contralateral striatum in the saline-treated
condition by a mean difference of 0.51 (95% CI 0.29 to 0.74;
p=0.002), and when comparing the mean side-to-side differences
for the Pgc-1a versus mCherry groups where the mean of the
differences was 0.7760.24 (95% CI 0.24 to 1.3; p=0.009). The
Pgc-1a dependent decrease in Bdnf expression in the Pgc-1a
overexpressing SN versus the contralateral SN is not apparent
after MPTP treatment (data not shown), which may represent
upregulation of Bdnf after MPTP treatment or, preferential loss of
the cells with lower levels of Bdnf expression on the Pgc-1a
overexpressing side.
Expression of the Transcription Factor Pitx3 is Reduced
by Pgc-1a Over-expression in the SN
Th, Dat, Vmat2 and Bdnf are all downstream of the transcription
factor Pitx3, whereas GDNF is upstream [42]. Pitx3 can also work
in concert with another transcription factor, Nurr1, to facilitate
expression of the dopaminergic phenotype [43]. SYBR-green
quantitative PCR revealed that over-expression of Pgc-1a resulted
in a significant down-regulation of Pitx3 to 0.2560.11 from a
0.7960.08 level of expression after mCherry (Figure 5C, 95% CI
0.23 to 0.85; p=0.003), a nonsignificant trend toward lower Nurr1
expression (0.4760.14 from 0.9360.18, a difference of
0.4660.24; 95% CI 20.08 to 1.0; p=0.08), and no loss of Lmx1b
expression relative to mCherry microinjected SN (1.2660.33 from
1.160.23, a difference of 20.1760.39; 95% CI 21.07 to 0.73;
p=0.677). Other transcription factors and co-activators (Atf4, Mta-
1 and Dj-1) were not affected (data not shown), indicating that the
effect of Pgc-1a on Pitx3 does not reflect a nonspecific global
suppression of transcription. We also confirmed a loss of Pitx3 at
the protein level (Figure 5D). Consistent with some crossing over of
Pgc-1a protein, and loss of Th, Vmat2 and Dat mRNA expression
in the contralateral SN (Figure 1E), this loss of Pitx3 protein was
observed to a lesser extent in the contralateral SN in addition to
the Pgc-1a overexpressing SN. Given the large loss of Pitx3 at the
protein level, it may be expected that we would see effects on Pitx3
target-gene expression in the contralateral SN. Post-hoc analysis of
dopaminergic marker gene expression data from the contralateral
(uninjected) SN, demonstrated that Pitx3 target genes (Th, Dat
and Vmat2) were indeed downregulated at the mRNA level in the
contralateral SN of Pgc-1a overexpressing animals compared to
the contralateral SN of mCherry overexpressing animals
(Figure 5E; p,0.0001 in all cases).
gross-dissected whole cell lysate SN and striatal samples (saline groups only). Band densitometry data was analyzed using a paired t-test to compare
Th-band intensity between the contralateral and ipsilateral (microinjected) SN and striatum (n=6 per group).
doi:10.1371/journal.pone.0048925.g004
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PLOS ONE | www.plosone.org 9 November 2012 | Volume 7 | Issue 11 | e48925Figure 5. Analysis of markers of the dopaminergic phenotype. A. SYBR-green PCR analysis of mRNA levels of Th, Dat and Vmat2 in mCherry
and Pgc-1a overexpressing SN samples (mCherry n=6, Pgc-1a n=5). B. Upper panel. SYBR-green PCR analysis of mRNA levels of Gdnf and Bdnf in
Pgc-1a SN samples. Fold-change in gene expression was calculated with respect to the contralateral SN using the DDCt method with normalization
to 18S. Data were analyzed using a one-sample t-test to determine if fold-change differed from the baseline value of 1 (n=6 per group). Lower panel.
Bdnf expression in mCherry and Pgc-1a overexpressing SN samples. Fold-change was calculated as before and the data were compared using
Student’s t-test (n=6 each group). C. SYBR-green PCR analysis of mRNA levels of Pitx3, Nurr1 and Lmx1b in mCherry and Pgc-1a overexpressing SN
samples. Fold-change in gene expression relative to the contralateral side was calculated as before and data were analyzed by comparing the mean
fold change between groups using a Student’s t-test (mCherry n=6, Pgc-1a n=5, except for Lmx1b where the analysis was performed on a separate
set of samples; mCherry n=6, Pgc-1a n=4). D. Western blot analysis of Pitx3 protein levels in pooled SN whole-cell lysate (same samples as 1D).
‘‘Cntrl’’ refers to the contralateral control side. E. SYBR-green PCR analysis of mRNA levels of Th, Dat and Vmat2 in the contralateral (cntrl) SN from
mCherry and Pgc-1a overexpressing mice. Fold-change gene expression was calculated in relation to the overall mean gene expression level for the
contralateral SN of all mCherry overexpressing animals (n=6 for both groups). Data were analyzed using a one-sample t-test to determine if fold-
change gene expression differed from 1. F. Schematic showing convergence of the genes found to be down-regulated after Pgc-1a overexpression,
on Pitx3.
doi:10.1371/journal.pone.0048925.g005
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the Dopaminergic Phenotype
To determine whether the effects observed in the SN after Pgc-
1a over-expression could be linked to the level of Pgc-1a over-
expression, a lower titer of the Pgc-1a vector, 1610
9 vgc in a
1.5 ml volume, was microinjected into the right SN of wild-type
C57BL/6CR mice (Figure 6A). This resulted in a mean 6.48-fold
increase in Pgc-1a expression (95% CI 1.4 to 11.54; p=0.02). With
this lower titer injection, the impact of Pgc-1a on the expression of
the subset of Pgc-1a-target genes examined was no longer
detectible. This may reflect a low sensitivity for detecting small
changes in gene expression levels since mRNA levels from tissue
homogenate were examined, which likely includes RNA from
many cells that were not transduced.
Although the effects were less pronounced, a significant 28.6%
loss of Th immunoreactivity in the striatum was observed
(Figure 6B) from 1.53610
6 AU on the contralateral side to
1.09610
6 on the ipsilateral side, a difference of 4.38610
5 AU
(95% CI 2.0610
5 to 6.7610
5; p=0.004), as was loss of DA, from
an average of 162 ng/mg protein to 102 ng/mg protein a
difference of 60.02 ng/mg protein (Figure 6C, 95% CI 6.034 to
114.0; p=0.035). DA turnover in the striatum (Figure 6D) also
increased from 0.1860.01 to 0.25860.002, an increase of 0.078
(95% CI 20.1378 to 20.018). Lesser in magnitude, but still
significant effects also were seen for downregulation of Th
(Figure 6E) to a mean expression level of 0.37 (95% CI 0.09 to
0.65; p=0.003), Dat to a mean expression level of 0.51 (95% CI
0.28 to 0.71; p=0.003), Vmat2 to a mean expression level of 0.64
(95% 0.11 to 0.62; p=0.02) and Pitx3 to a mean expression level
of 0.26 (95% CI 0.57 to 0.92; p=0.0003) mRNA levels in the
ipsilateral SN compared to the contralateral side. These data are
consistent with suppression of the dopaminergic phenotype by
Pgc-1a even with these lower titer injections.
Discussion
PGC-1a is a transcriptional co-activator that can induce
mitochondrial biogenesis and upregulate antioxidant defenses
[44] [6,22]. This, along with the finding of low expression of PGC-
1a target genes in SN neurons in early PD [30], has led to the
suggestion that increasing PGC-1a activity may be neuroprotec-
tive in Parkinson’s disease. However, data presented here indicate
that there may be unintended and deleterious effects of viral
overexpression of Pgc-1a in the SN.
We achieved a robust level of Pgc-1a expression at the mRNA
level, and increased expression of the Pgc-1a-target genes Prdx3,
Prdx5 and Cycs (with high titer injections) coupled with an increase
in the mitochondrial marker CoxIV in the SN after MPTP
treatment, indicating that the overexpressed Pgc-1a was function-
al. We also detected Pgc-1a protein expression; albeit low levels of
the full-length Pgc-1a isoform, which may be expected for a
transcriptional co-activator with a short half-life [45,46] [47].
Although our AAV2/10-EGFP virus spread well throughout the
SN and was capable of transducing Th+ cells, we had difficulty
finding convincing co-localization of Pgc-1a and Th in neurons
after microinjection of AAV2/10-FHA-Pgc-1a. While this was
initially surprising, the likely reason for this observation (down-
regulation of Th expression by Pgc-1a) became clear after further
investigation.
Another unexpected finding was that we observed no evidence
of neuroprotection after Pgc-1a overexpression, and in fact,
observed enhanced vulnerability to MPTP as evidenced by
reduced numbers of total neurons by stereological cell counts in
the SN. This was particularly unexpected since Pgc-1a knockout
animals are more sensitive to MPTP toxicity [6], and other recent
work suggests that constitutive transgenic overexpression of Pgc-1a
from the Thy1 promoter may be protective against MPTP toxicity
[34]. In addition, we observed substantial depletion of dopamine
(independent of MPTP toxicity) as a result of Pgc-1a overexpres-
sion in the SN, a potentially deleterious effect if considering PGC-
1a as a neuroprotective strategy for PD. Together, these data raise
the possibility that there may be a narrow window of optimal
activity of PGC-1a, whereby either too little or too much is
detrimental, a conclusion that is consistent with the precise
regulation of PGC-1a activity that normally occurs.
The observed deleterious effects may reflect the high levels of
Pgc-1a activity achieved via viral vector microinjection. Unfortu-
nately, quantification of the level of Pgc-1a mRNA or protein has
not been reported in many of the published overexpression studies,
making it difficult to compare levels of expression between studies.
In addition, in the case of transgenic overexpression of Pgc-1a,
compensatory changes associated with overexpression throughout
development could contribute to the fact that transgenic mice were
protected against MPTP toxicity, whereas we detect increased
sensitivity to MPTP with viral Pgc-1a overexpression in adult wild-
type mice.
While this manuscript was in preparation another article also
identified deleterious effects resulting from viral overexpression of
PGC-1a in the nigro-striatal system [35]. These authors used an
AAV2/6 viral vector to induce a 400-fold increase in PGC-1a
mRNA in rat SN, and observed Th+ neuronal loss in the absence
of any other treatment. In our study, AAV2/10 mediated Pgc-1a
overexpression induced loss of dopaminergic markers without
inducing overt neuronal death, suggesting that additional toxicities
may become apparent at higher levels of overexpression.
Consistent with this, these authors observed only a ‘minimal
impact’ on survival of Th+ SN neurons with lower-levels of PGC-
1a expression in the SN (achieved with injections in the striatum
rather than directly into the SN), further indicating that the level of
PGC-1a overexpression may be crucial. The time-period post Pgc-
1a expression may also be an important factor in observing Th+
cell death. In the previously published study, rats were sacrificed 3
months after PGC-1a overexpression, considerably longer than our
7-week interval in mice.
In the current study, levels of Pgc-1a mRNA expression at time
of sacrifice ranged from a 13-fold increase to a 122-fold increase
relative to the contralateral side for the higher titer injections and
from 1.6-fold to 13-fold for the lower titer injections. Since mRNA
levels were measured from gross dissected SN tissue, and not every
cell in the SN was transduced by the virus, it is likely that the level
of expression in individual transduced cells was much higher than
the average fold-change values obtained, and that such high levels
of expression may have deleterious effects that outweigh any
potential protective actions.
There is a precedent for adverse effects reported in association
with PGC-1a overexpression, particularly in muscle tissues
[48,49], which may be linked to linked to excessive proliferation
of mitochondria. In our study, levels of the mitochondrial marker
CoxIV were not increased in the AAV2/10-FHA-Pgc-1a micro-
injected SN at baseline (saline treatment) relative to the
contralateral SN, and although the levels of CoxIV were increased
in the AAV2/10-FHA-Pgc-1a microinjected SN relative to the
contralateral SN after MPTP-treatment, there was no statistically
significant difference between CoxIV band intensity in the Pgc-1a
microinjected SNs when comparing SNs of saline versus MPTP
treated mice. Therefore, the increase in CoxIV levels in the
MPTP-treated mice likely represents maintenance of CoxIV levels
as a result of Pgc-1a expression in the presence of MPTP.
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PLOS ONE | www.plosone.org 11 November 2012 | Volume 7 | Issue 11 | e48925Figure 6. Data from lower-titer injections. A. SYBR-green PCR analysis of Pgc-1a and Pgc-1a target gene mRNA levels after saline treatment in
mice microinjected unilaterally into the right SN with AAV2/10-FHA-Pgc-1a or AAV2/10-mCherry. mRNA levels were normalized to 18S and fold-
change gene expression was calculated relative to the contralateral SN using the DDCt method. Data were analyzed using a paired t-test (n=6). B.
Striatal Th immunoreactivity data for the contralateral side (Cntrl) compared to the ipsilateral side microinjected in the SN with AAV2/10-FHA-PGC-1a.
Ipsilateral and contralateral striatal Th immunoreactivity within each treatment group was analyzed using a paired t-test (n=7). C. Mean levels of
striatal DA per mg of protein in the ipsilateral and contralateral (cntrl) striatum of mice microinjected unilaterally with a lower titer of AAV2/10-FHA-
PGC-1a. Data were analyzed by paired t-test (n=5). D. DA turnover in each treatment group. Data were analyzed by paired t-test for within group
comparisons and Student’s t-test for between group comparisons. E. SYBR-green PCR analysis of dopaminergic markers. Fold change in gene
expression relative to the contralateral side was calculated as before. Data were analyzed using a one-sample t-test to determine if fold-change gene
expression differed from 1 (n=5). F. SYBR-green PCR analysis of Pitx3 and Nurr1 expression (n=5). Fold change was calculated and data were
analyzed as in E.
doi:10.1371/journal.pone.0048925.g006
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loss of striatal DA, and Th staining, in the Pgc-1a overexpressing
mice after MPTP treatment, compared to saline treatment. This,
in conjunction with lower total SN neuronal counts, indicates an
increased sensitivity to MPTP at this level of Pgc-1a overexpres-
sion. Potentially, this could be linked to Bdnf downregulation at
baseline. BDNF is an important neurotrophic factor for dopami-
nergic neurons [50,51], is reduced in the SN in PD [52,53]and
many studies have shown that overexpression of Bdnf is protective
in experimentally-induced PD models [50,54–56]. In addition, it
may be that Bdnf and Th act synergistically in enhancing
dopaminergic cell survival in response to a neurotoxic insult
[57], a point that is particularly relevant to this work given the
observed downregulation of Th in response to Pgc-1a overex-
pression.
Recent work has shown that Bdnf is a downstream target of
Gdnf and Pitx3 [42], a transcription factor involved in the
development and maintenance of dopaminergic neurons [58–60].
Pitx3 also mediates the expression of Th, Vmat2 and Dat [61–62]
[63,64], which we found to be strongly downregulated in response
to Pgc-1a overexpression, both in the presence and absence of
MPTP administration. Therefore, we hypothesized, and subse-
quently confirmed, that viral overexpression of Pgc-1a downreg-
ulates Pitx3 expression in the SN. The downregulation of Pitx3
provides a link between Bdnf, Th, Vmat2, Dat mRNA downregu-
lation in this system (Figure 5F). Consistent with this, levels of Gdnf,
which is upstream of Pitx3, were not altered by Pgc-1a. In light of
the recent finding by Peng et al [42] that Pitx3 mediates Gdnf-
induced upregulation of Bdnf, it will be interesting to determine
how many of the effects on Th cells historically attributed to Gdnf
are mediated by the effect of Gdnf on Pitx3 and Bdnf.
Given the well-established key role of Pitx3 in Th expression,
which is required for DA synthesis, it is likely that downregulation
of Pitx3 contributes to the DA depletion that we observed
following unilateral overexpression of Pgc-1a. However, Bdnf may
be involved in this as Bdnf has been implicated in the positive
regulation of Th expression during development [65].
Several lines of data demonstrate that downregulation of Pitx3
and Pitx3 target gene expression is not reflective of a nonspecific
global downregulation of transcription. Levels of Tubb3, a
neuronal marker, were not altered by Pgc-1a expression. Also,
other mRNAs were found to be unaltered by Pgc-1a, including
levels of Gdnf, as well as expression of several other transcription
factors and co-activators (Atf4, Lmx1b, Mta-1 and Dj-1).
Th was downregulated at both the mRNA level and at the
protein level, as measured by qPCR, immunohistochemistry and
western blot. In contrast, Dat was only downregulated at the
mRNA level, whereas Dat immunostaining in the striatum was
similar between mCherry and Pgc-1a overexpressing animals. The
disparity between Dat mRNA and protein levels may be due to
temporal factors; i.e. although transcription of Dat is reduced, the
degradation of membrane-spanning and membrane associated
Dat protein by the endosomal/lysosomal pathway [66] has not yet
proceeded to a level where the reduced replenishment of Dat
protein is detectable. In contrast cytosolic Th, which is noticeably
and quantifiably lost at the protein level in this system, is primarily
degraded in a more rapid manner by the proteasome [67–68].
This work demonstrates that viral vector mediated overexpres-
sion of full-length Pgc-1a in the SN does not protect against
MPTP-induced neuronal loss and DA depletion. Indeed, viral
overexpression of Pgc-1a potentiated MPTP toxicity in Th+
neurons. Our data further show that Pgc-1a induces loss of the
dopaminergic phenotype in SN neurons, potentially due, to
reduced Pitx3 expression. While Pgc-1a induced DA depletion is
an important concern for the use of full-length Pgc-1a gene
therapy as a neuroprotective in PD, it is unlikely to have direct
ramifications for Pgc-1a overexpression strategies in other areas of
the brain since the expression of Pitx3 is localized to midbrain
neurons. Although Pitx3 suppression likely contributes to the
downregulation of the dopaminergic phenotype associated with
Pgc-1a overexpression, further studies are needed to elucidate the
mechanism by which Pgc-1a downregulates Pitx3. PGC-1a
remains in theory a promising target for neuroprotection, but
careful attention to the precise levels of PGC-1a expression and
the method of Pgc-1a modulation [69] will likely be necessary in
order to achieve the protective potential of PGC-1a while avoiding
its potentially deleterious effects.
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